<DOC>
	<DOCNO>NCT02696434</DOCNO>
	<brief_summary>This study evaluate efficacy , safety , tolerability oral naltrexone use conjunction buprenorphine adult Opioid Use Disorder transition buprenorphine maintenance prior first dose VIVITROL .</brief_summary>
	<brief_title>Evaluating Naltrexone Use Conjunction With Buprenorphine Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior First Dose VIVITROL</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Willing able provide inform consent Willing able provide governmentissued identification Has Body Mass Index ( BMI ) 18.040.0 kg/m^2 Has history opioid use disorder diagnosis least 6 month Has history prescribe buprenorphine ( buprenorphine/naloxone ) maintenance prior 3 consecutive month currently buprenorphinemaintained Must voluntarily seek treatment opioid use disorder motivate receive antagonist therapy Willing abide contraception requirement duration study Additional criterion may apply Is pregnant , plan become pregnant breastfeeding study Has positive urine drug screen morphine oxycodone screening Has use methadone within 30 day prior study Day 5 Has use naltrexone ( oral VIVITROL ) within 90 day prior Day 5 Has history seizure receive anticonvulsant therapy within past 5 year treatment seizure ( use anticonvulsant past detoxification exclusionary ) Has condition , disease state , previous medical history would preclude safe participation study affect ability adhere protocol visit schedule , requirement , assessment Has current diagnosis schizoaffective disorder , bipolar disorder , untreated unstable major depressive disorder Is currently physiologically dependent psychoactive substance ( except opioids , caffeine , nicotine ) require medical intervention detoxification Has history hypersensitivity adverse reaction buprenorphine , naltrexone , VIVITROL , naloxone Additional criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>naltrexone</keyword>
	<keyword>VIVITROL</keyword>
	<keyword>buprenorphine</keyword>
	<keyword>opioid</keyword>
	<keyword>addiction</keyword>
</DOC>